No Data
No Data
Roth MKM Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $19
Roth MKM analyst Jonathan Aschoff maintains $Zevra Therapeutics(ZVRA.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 28.9% a
Zevra Therapeutics Files $350 Million Mixed-Shelf; Shares Fall After Hours
Zevra Therapeutics (ZVRA) filed a shelf registration statement with the US Securities and Exchange Commission Tuesday covering the potential sale of up to $350 million of its securities from time to t
Express News | Zevra Therapeutics has submitted an application for mixed shelf offering to SEC, with a maximum value of $350 million.
Express News | Zevra Therapeutics Inc Files for Mixed Shelf Offering of up to $350 Mln- SEC Filing
Express News | Zevra Therapeutics Inc - Kp1077 has good tolerance.
Express News | Zevra Therapeutics Inc - Kp1077 Was Well Tolerated
No Data